Skip to main content
. 2020 Apr 18;21(8):2825. doi: 10.3390/ijms21082825

Figure 3.

Figure 3

Effects of the combination of an AKT inhibitor (AZD5363) and mTOR inhibitors (AZD2014 and BEZ235) on the proliferation of PI3KCA and mTOR-mutated bladder cancer cells. (A) The combination therapy with AZD5363 (3 μM) and mTOR inhibitors (1 μM AZD2014 and 0.5 μM BEZ235) exerted synergistic inhibitory effects on the growth of J82 cells. (B) The effects of the combination therapy on J82 cells were determined using the colony formation assay. (C) The effects of the combination therapy on PI3K/AKT/mTOR signaling pathway in J82 cells were detected by Western blot analysis. Cells were treated with drugs for 24 h.